Literature DB >> 28343230

Idiopathic Pulmonary Fibrosis in Switzerland: Diagnosis and Treatment.

Manuela Funke-Chambour1, Andrea Azzola, Dan Adler, Constance Barazzone-Argiroffo, Christian Benden, Annette Boehler, Pierre-Olivier Bridevaux, Martin Brutsche, Christian F Clarenbach, Katrin Hostettler, Rebekka Kleiner-Finger, Laurent P Nicod, Paola M Soccal, Michael Tamm, Thomas Geiser, Romain Lazor.   

Abstract

Idiopathic pulmonary fibrosis (IPF) is a severe progressive and irreversible lung disease. Novel antifibrotic drugs that slow disease progression are now available. However, many issues regarding patient management remain unanswered, such as the choice between available drugs, their use in particular subgroups and clinical situations, time of treatment onset, termination, combination or switch, or nonpharmacologic management. To guide Swiss respiratory physicians in this evolving field still characterized by numerous areas of uncertainty, the Swiss Working Group for interstitial and rare lung diseases of the Swiss Respiratory Society provides a position paper on the diagnosis and treatment of IPF.
© 2017 S. Karger AG, Basel.

Entities:  

Mesh:

Year:  2017        PMID: 28343230     DOI: 10.1159/000464332

Source DB:  PubMed          Journal:  Respiration        ISSN: 0025-7931            Impact factor:   3.580


  7 in total

Review 1.  [The multidisciplinary discussion-the gold standard in diagnosing interstitial lung diseases].

Authors:  Sabina Berezowska; Manuela Funke-Chambour; Alexander Pöllinger; Stephan C Schäfer
Journal:  Pathologe       Date:  2020-02       Impact factor: 1.011

2.  Real-World Experience with Nintedanib in Patients with Idiopathic Pulmonary Fibrosis.

Authors:  Eva Brunnemer; Julia Wälscher; Svenja Tenenbaum; Julia Hausmanns; Karen Schulze; Marianne Seiter; Claus Peter Heussel; Arne Warth; Felix J F Herth; Michael Kreuter
Journal:  Respiration       Date:  2018-02-28       Impact factor: 3.580

Review 3.  Idiopathic Pulmonary Fibrosis: Best Practice in Monitoring and Managing a Relentless Fibrotic Disease.

Authors:  Wim A Wuyts; Marlies Wijsenbeek; Benjamin Bondue; Demosthenes Bouros; Paul Bresser; Carlos Robalo Cordeiro; Ole Hilberg; Jesper Magnusson; Effrosyni D Manali; António Morais; Spyridon Papiris; Saher Shaker; Marcel Veltkamp; Elisabeth Bendstrup
Journal:  Respiration       Date:  2019-12-12       Impact factor: 3.580

4.  Critical appraisal of the quality of clinical practice guidelines for idiopathic pulmonary fibrosis.

Authors:  Xuanlin Li; Xueqing Yu; Yang Xie; Zhenzhen Feng; Yanfang Ma; Yaolong Chen; Jiansheng Li
Journal:  Ann Transl Med       Date:  2020-11

5.  Evaluation of a Novel Ear Pulse Oximeter: Towards Automated Oxygen Titration in Eyeglass Frames.

Authors:  Fabian Braun; Christophe Verjus; Josep Solà; Marcus Marienfeld; Manuela Funke-Chambour; Jens Krauss; Thomas Geiser; Sabina A Guler
Journal:  Sensors (Basel)       Date:  2020-06-10       Impact factor: 3.576

Review 6.  Oxygen therapy in COPD and interstitial lung disease: navigating the knowns and unknowns.

Authors:  Yet H Khor; Elisabetta A Renzoni; Dina Visca; Christine F McDonald; Nicole S L Goh
Journal:  ERJ Open Res       Date:  2019-09-16

Review 7.  Ongoing challenges in pulmonary fibrosis and insights from the nintedanib clinical programme.

Authors:  Claudia Valenzuela; Sebastiano Emanuele Torrisi; Nicolas Kahn; Manuel Quaresma; Susanne Stowasser; Michael Kreuter
Journal:  Respir Res       Date:  2020-01-06
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.